Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

Mutant RAS has remained recalcitrant to targeted therapy efforts. Here we demonstrate that combined treatment with poly ADP ribose polymerase (PARP) inhibitors and MEK inhibitors evokes unanticipated, synergistic cytotoxic effects in vitro and in vivo in multiple RAS mutant tumor models across tumor...

Full description

Saved in:
Bibliographic Details
Published in:Sci Transl Med
Main Authors: Sun, Chaoyang, Fang, Yong, Yin, Jun, Chen, Jian, Ju, Zhenlin, Zhang, Dong, Chen, Xiaohua, Vellano, Christopher P., Jeong, Kang Jin, Ng, Patrick Kwok-Shing, Eterovic, A. Karina, Bhola, Neil H., Lu, Yiling, Westin, Shannon N, Grandis, Jennifer R., Lin, Shiaw-Yih, Scott, Kenneth L., Peng, Guang, Brugge, Joan, Mills, Gordon B.
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5919217/
https://ncbi.nlm.nih.gov/pubmed/28566428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal5148
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items